Core Viewpoint - Shenzhen Hanno Medical Technology Co., Ltd. has submitted its IPO application to the Shanghai Stock Exchange for listing on the Sci-Tech Innovation Board, marking a significant milestone as the first domestic company to achieve market approval for ECMO systems, indicating a key leap in China's high-end life support equipment sector [1] Financial Performance - Hanno Medical is experiencing rapid growth, with revenue projected to increase from 29.83 million yuan in 2023 to 49.31 million yuan in 2024, and 37.36 million yuan in the first half of 2025; losses are expected to narrow significantly from 341 million yuan in 2023 to 82.27 million yuan in the first half of 2025 [2] - The company has completed 10 rounds of financing since its establishment, attracting investments from notable institutions, reflecting strong market recognition of its technological capabilities and growth prospects [2] - The company plans to raise 1.06 billion yuan through its public offering, which will be allocated to R&D, production, marketing network development, and working capital, aligning with its long-term strategy and national policies promoting domestic high-end medical equipment [2] Technological Innovation - Hanno Medical emphasizes independent innovation, having developed all key technologies in-house, maintaining a significant competitive edge in the industry; it has mastered seven core technologies and holds 38 authorized patents, establishing a robust technological foundation for future product development [3][4] Market Position and Product Development - The company's core product, the Lifemotion ECMO system, received market approval in 2023, breaking the long-standing technological monopoly held by countries like the US, Germany, and Italy; it also obtained EU CE MDR certification in early 2025, marking it as the first domestic ECMO product to enter the international market [4][6] - Hanno Medical's product offerings span a comprehensive range of life support solutions, including ECMO, ECPR, CPS, and Low-Flow systems, demonstrating clear clinical value and sustainable commercial growth potential [5] International Expansion - As of June 30, 2025, the Lifemotion ECMO system has been adopted by over 140 hospitals in China, including top-tier institutions, and has successfully entered international markets in Europe, South America, and Africa, with ongoing product registration efforts in various countries [6][7] - The CE certification signifies that Hanno Medical's products meet international standards for quality, safety, and effectiveness, enhancing global market trust and enabling participation in international competition [7] Industry Growth Potential - The ECMO industry is projected to grow significantly, with the Chinese market expected to expand from 960 million yuan in 2024 to 3.71 billion yuan by 2030, reflecting a compound annual growth rate of 25.2%; the global market is anticipated to reach 5.8 billion USD by 2035 [8] - Hanno Medical has established a sustainable business model centered on "equipment first, consumables driven," ensuring predictable cash flow and market penetration, with plans to replicate this model in international markets [9]

Group 1 - The high-pressure oxygen chamber concept increased by 2.20%, ranking fourth among concept sectors, with eight stocks rising, including Jinling Pharmaceutical, BeiYikang, and Innovation Medical, which rose by 6.35%, 5.73%, and 3.79% respectively [1] - The main capital inflow for the high-pressure oxygen chamber concept was 0.29 billion yuan, with five stocks receiving net inflows, led by Innovation Medical with a net inflow of 52.09 million yuan [2][3] - The net inflow ratios for International Medical, Innovation Medical, and Jinling Pharmaceutical were 9.48%, 5.21%, and 3.12% respectively, indicating strong investor interest in these stocks [3] Group 2 - The top gainers in the high-pressure oxygen chamber concept included Innovation Medical, International Medical, and Jinling Pharmaceutical, while the top losers were Samsung Medical and Hangyang Co., which fell by 3.20% and 1.14% respectively [1][4] - The trading volume for Innovation Medical was 11.31%, indicating a high turnover rate, while other stocks like International Medical and Jinling Pharmaceutical had lower turnover rates of 1.77% and 4.54% respectively [3]

Group 1 - The core point of the news is that QuanZhen Medical is undergoing a B+ round financing to support its business development, with investments from multiple partners [1] - The company has agreed to sign the B+ round capital increase agreement and shareholder agreement with the investors [1] - After the capital increase and share transfer, the company's stake will be 16.5160% [1] Group 2 - According to the B+ round capital increase agreement, Puhua Zhongxiao will invest RMB 20 million, subscribing to an increase in registered capital of RMB 1.180579 million [2] - Changzhou Hengnuo and the Talent Fund will each invest RMB 5 million, subscribing to an increase in registered capital of RMB 0.295145 million [2] - Following the capital increase, the registered capital of QuanZhen Medical will rise to RMB 165.28106 million, with Puhua Zhongxiao, Changzhou Hengnuo, and the Talent Fund acquiring 7.1429%, 1.7857%, and 1.7857% equity respectively [2]

Group 1 - The core point of the news is that QuanZhen Medical is conducting a B+ round financing to support its business development, with investments from three entities: Puhua Zhongxiao, Changzhou Hengnuo, and the Talent Fund [1] - The board of QuanZhen Medical has approved the signing of the B+ round capital increase agreement and related documents, resulting in the company's stake being 16.5160% after the financing [1] Group 2 - According to the B+ round capital increase agreement, Puhua Zhongxiao will invest RMB 20 million, acquiring 7.1429% equity in QuanZhen Medical, while Changzhou Hengnuo and the Talent Fund will each invest RMB 5 million, acquiring 1.7857% equity [2] - The registered capital of QuanZhen Medical will increase to RMB 1,652.8106 million following this financing round [2]

日前，公司董事会审议通过了《关于同意签署参股公司全诊医学〈B+轮增资协议〉〈B+轮股东协议〉 及相关文件的议案》。根据全诊医学《B+轮增资协议》，本次增资方案为：普华中小以货币形式出资 2000万元，认缴全诊医学本次B+轮新增注册资本118.0579万元;常州恒诺以货币形式出资500万元，认缴 全诊医学本次B+轮新增注册资本29.5145万元;人才基金以货币形式出资500万元，认缴全诊医学本次 B+轮新增注册资本29.5145万元。全诊医学注册资本增加至1652.8106万元，普华中小、常州恒诺、人才 基金分别获得全诊医学本次增资后的7.1429%股权、1.7857%股权、1.7857%股权。全诊医学实施本次增 资及转股方案后，公司的出资额占比为16.5160%。 创新医疗（002173）(002173.SZ)公告，现公司参股公司全诊医学因业务发展需要进行B+轮融资，确定 接受普华中小二期(杭州)创业投资合伙企业(有限合伙)(简称"普华中小")、常州恒诺数智创业投资合伙企 业(有限合伙)(简称"常州恒诺")、杭州高层次人才创新创业投资合伙企业(有限合伙)(简称"人才基金")的 投资。 ...

日前，公司董事会审议通过了《关于同意签署参股公司全诊医学〈B+轮增资协议〉〈B+轮股东协议〉 及相关文件的议案》。根据全诊医学《B+轮增资协议》，本次增资方案为：普华中小以货币形式出资 2000万元，认缴全诊医学本次B+轮新增注册资本118.0579万元;常州恒诺以货币形式出资500万元，认缴 全诊医学本次B+轮新增注册资本29.5145万元;人才基金以货币形式出资500万元，认缴全诊医学本次 B+轮新增注册资本29.5145万元。全诊医学注册资本增加至1652.8106万元，普华中小、常州恒诺、人才 基金分别获得全诊医学本次增资后的7.1429%股权、1.7857%股权、1.7857%股权。全诊医学实施本次增 资及转股方案后，公司的出资额占比为16.5160%。 智通财经APP讯，创新医疗(002173.SZ)公告，现公司参股公司全诊医学因业务发展需要进行B+轮融 资，确定接受普华中小二期(杭州)创业投资合伙企业(有限合伙)(简称"普华中小")、常州恒诺数智创业投 资合伙企业(有限合伙)(简称"常州恒诺")、杭州高层次人才创新创业投资合伙企业(有限合伙)(简称"人才 基金")的投资。 ...

（记者 曾健辉） 截至发稿，创新医疗市值为93亿元。 每经头条（nbdtoutiao）——专访管涛：美国政府经济贸易政策正逐渐动摇美元本位国际货币体系，利 多因素下人民币汇率有可能破7 每经AI快讯，创新医疗（SZ 002173，收盘价：20.98元）12月12日晚间发布公告称，公司第七届2025年 第四次董事会临时会议于2025年12月11日以通讯表决方式召开。会议审议了《关于同意签署参股公司全 诊医学〈B+轮增资协议〉〈B+轮股东协议〉及相关文件的议案》等文件。 2025年1至6月份，创新医疗的营业收入构成为：医疗服务业务占比99.73%，其他业务占比0.27%。 ...

证券代码：002173 证券简称：创新医疗 公告编号：2025-056 创新医疗管理股份有限公司 关于签署参股公司全诊医学《B+轮增资协议》 《B+轮股东协议》及相关文件的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次交易概述 （一）交易基本情况 创新医疗管理股份有限公司（以下简称"公司"）于 2024 年 8 月 28 日召开 的第六届董事会 2024 年第六次临时会议，审议通过了《关于投资杭州全诊医学 科技有限公司的议案》，同意公司对杭州全诊医学科技有限公司（以下简称"全 诊医学"）进行战略投资，具体内容详见公司 2024 年 8 月 29 日、2024 年 11 月 1 日发布于巨潮资讯网（http://www.cninfo.com.cn）的相关公告。 公司于 2025 年 6 月 30 日召开了第六届董事会 2025 年第五次临时会议，审 议通过了《关于同意签署参股公司全诊医学〈B 轮增资及转股协议〉〈B 轮股东 协议〉及相关文件的议案》，同意公司签署《杭州全诊医学科技有限公司 B 轮增 资及转股协议》《杭州全诊医学科技有限公司 B 轮 ...

证券代码：002173 证券简称：创新医疗 公告编号：2025-055 创新医疗管理股份有限公司 第七届董事会 2025 年第四次临时会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 创新医疗管理股份有限公司（以下简称"公司"）第七届董事会于 2025 年 12 月 11 日召开了 2025 年第四次临时会议。本次会议以通讯表决方式召开。会 议通知于 2025 年 12 月 9 日以书面形式发出。本次会议由陈海军董事长主持，应 出席董事 9 名，实际出席 9 名。本次会议召开符合《公司法》及公司《章程》的 规定，合法有效。 二、董事会会议审议情况 与会董事就议案进行了审议、表决，以 9 票赞成、0 票反对、0 票弃权的表 决结果一致通过了《关于同意签署参股公司全诊医学〈B+轮增资协议〉〈B+轮股 东协议〉及相关文件的议案》。 同意公司签署《杭州全诊医学科技有限公司 B+轮增资协议》、《杭州全诊医 学科技有限公司 B+轮股东协议》以及杭州全诊医学科技有限公司（以下简称"全 诊医学"）本轮增资所涉股东会决议等相关文件，同意公司放 ...

创新医疗公告称，公司第七届董事会2025年第四次临时会议以通讯表决方式召开，9名董事全部出席。 会议以9票赞成、0票反对、0票弃权，一致通过《关于同意签署参股公司全诊医学〈B+轮增资协议〉 〈B+轮股东协议〉及相关文件的议案》，同意签署全诊医学B+轮增资等相关文件，并放弃本次融资中 的优先认购权或其他类似权利。 ...